The research showed that alternative TLN2 and ZNF521 genotypes explained significant inter-patient variation in relative abundance of two key pathogens. Wound diversity was lowest in Pseudomonas aeruginosa infected wounds, which had a significant negative linear relationship with healing rate.
An exclusive Clinical OMICs conversation with the director of Genomes2People, Robert Green, M.D., MPH.
Hailed for its gene editing power, Sherlock Bioscience’s COVID-19 diagnostic is the first CRISPR technology to gain FDA approval.Hailed for its gene editing power, Sherlock Bioscience’s COVID-19 diagnostic is the first CRISPR technology to gain FDA approval.
The company will expand its health benefits management offerings, as well as make investments in data analytics and innovative health tech
Sherlock Biosciences and binx health said they plan to develop the world’s first rapid, point-of-care diagnostic test for COVID-19 using CRISPR technology.
This year’s list of innovative companies have all found, or developed, technology solutions that have allowed them to become innovators in their niche.
The company says it will use the funds to “expand its patient engagement and care navigation platform for cancer, reproductive health and pharmacogenomics to bring the benefits of genomic medicine to a wider U.S. population.”
GenapSys’ sequencing system is about the size of an iPad, costs under $10,000, and is based on a proprietary direct electronic sequencing chip, which is intended to eliminate the need for cumbersome equipment.
Up-and-Coming Diagnostic Test Developers Emerge as Consolidation Thins the Field.
Company expects to deliver 50,000 tests per day of the rapid, instrument-based, isothermal system designed for qualitative detection of infectious diseases.